Shane Hegarty

Company: Axonis

Job title: Chief Scientific Officer & Co-Founder

Seminars:

In Vivo Phenotypic Screens to Identify Novel Therapeutic Targets to Treat Conserved Pathologies in Neurodegenerative Disorders 11:30 am

Unbiased in vivo phenotypic screens can discover novel therapeutic targets underlying conserved pathological problems in neurodegenerative disorders Identifying neuro-protective/-regenerative therapies to preserve spared neuronal populations affected by progressive, chronic neurodegenerative diseases. Developing KCC2 neuromodulation therapies for neurodegenerative disorders involving excitation/inhibition imbalance and neuronal circuit disinhibition within the CNSRead more

day: Conference Day One - Track One